Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) Director Adam K. Stern acquired 15,000 shares of the company’s stock in a transaction on Monday, June 10th. The stock was bought at an average price of $0.82 per share, for a total transaction of $12,300.00. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website.
Matinas BioPharma stock traded down $0.03 during trading hours on Tuesday, hitting $0.81. The company had a trading volume of 618,585 shares, compared to its average volume of 1,041,284. Matinas BioPharma Holdings Inc has a fifty-two week low of $0.32 and a fifty-two week high of $1.50.
Matinas BioPharma (NYSEAMERICAN:MTNB) last released its quarterly earnings data on Monday, May 13th. The company reported ($0.04) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.03) by ($0.01).
Several institutional investors and hedge funds have recently made changes to their positions in the company. Vivo Capital LLC acquired a new position in shares of Matinas BioPharma during the 1st quarter worth $7,432,000. Broadfin Capital LLC acquired a new position in shares of Matinas BioPharma during the 1st quarter worth $2,973,000. Victory Capital Management Inc. acquired a new position in shares of Matinas BioPharma during the 1st quarter worth $1,867,000. J. Goldman & Co LP acquired a new position in shares of Matinas BioPharma during the 1st quarter worth $1,139,000. Finally, BlackRock Inc. increased its stake in shares of Matinas BioPharma by 107.7% during the 1st quarter. BlackRock Inc. now owns 603,583 shares of the company’s stock worth $658,000 after purchasing an additional 312,994 shares during the last quarter.
Several research firms have weighed in on MTNB. Zacks Investment Research lowered shares of Matinas BioPharma from a “buy” rating to a “sell” rating in a research note on Wednesday, May 22nd. BTIG Research began coverage on shares of Matinas BioPharma in a research note on Friday, May 17th. They issued a “buy” rating and a $5.00 price objective on the stock. Maxim Group reiterated a “buy” rating and issued a $5.00 price objective on shares of Matinas BioPharma in a research note on Thursday, May 16th. Finally, Roth Capital began coverage on shares of Matinas BioPharma in a research note on Monday, February 11th. They issued a “buy” rating and a $4.75 price objective on the stock.
COPYRIGHT VIOLATION WARNING: “Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) Director Adam K. Stern Purchases 15,000 Shares” was originally reported by Sundance Herald and is the sole property of of Sundance Herald. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States and international trademark and copyright legislation. The original version of this story can be accessed at https://sundanceherald.com/2019/06/11/matinas-biopharma-holdings-inc-nyseamericanmtnb-director-adam-k-stern-purchases-15000-shares.html.
About Matinas BioPharma
Matinas BioPharma Holdings, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. The company enables the delivery of life-changing medicines using its lipid nano-crystal (LNC) platform technology. Its LNC delivery technology platform utilizes lipid nano-crystals which can encapsulate small molecules, oligonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable.
Featured Article: Outstanding Shares, Buying and Selling Stocks
Receive News & Ratings for Matinas BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.